A novel galectin-1 inhibitor discovered through one-bead two-compound library potentiates the antitumor effects of paclitaxel in vivo

Molecular Cancer Therapeutics

Volumn 16, Issue 7, 2017, Pages 1212-1223

  Shih, Tsung Chieh ^a   Liu, Ruiwu ^a   Fung, Gabriel ^a   Bhardwaj, Gaurav ^b   Ghosh, Paramita M ^a,c,d   Lam, Kit S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GALECTIN 1; K RAS PROTEIN; LLS 2; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SCREENING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MOLECULAR LIBRARY; MOUSE; NONHUMAN; ONCOGENE H RAS; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; GALECTIN 1; HUMANS; MICE; NEOPLASMS; PACLITAXEL; SMALL MOLECULE LIBRARIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85018409313     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0690     Document Type: Article

References (46)

1. Engel A, Gaub HE. Structure and mechanics of membrane proteins. Annu Rev Biochem 2008;77:127–48.
2. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004;4:499–511.
3. Ritter SL, Hall RA. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol 2009;10:819–30.
4. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013;12:147–68.
5. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169–81.
6. Piechocki MP, Wu GS, Jones RF, Jacob JB, Gibson H, Ethier SP, et al. Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. Int J Cancer 2012; 131:2562–72.
7. Sivakumar R, Pradeepchandran R, Jayaveera KN, Kumarnallasivan P, Vijaianand PR, Venkatnarayanan R. Benzimidazole: an attractive pharmacophore in medicinal chemistry. IJPR 2011;3:19–31.
8. Lam KS, Salmon SE, Hersh EM, Hruby VJ, Kazmierski WM, Knapp RJ. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 1991;354:82–4.
9. Sweeney MC, Pei D. An improved method for rapid sequencing of support-bound peptides by partial edman degradation and mass spectrometry. J Comb Chem 2003;5:218–22.
10. Marani MM, Oliveira E, Cote S, Camperi SA, Albericio F, Cascone O. Identification of protein-binding peptides by direct matrix-assisted laser desorption ionization time-of-flight mass spectrometry analysis of peptide beads selected from the screening of one bead-one peptide combinatorial libraries. Anal Biochem 2007;370:215–22.
11. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol 2006;2:381–9.
12. Meldal M. The one-bead two-compound assay for solid phase screening of combinatorial libraries. Biopolymers 2002;66:93–100.
13. Kumaresan PR, Wang Y, Saunders M, Maeda Y, Liu R, Wang X, et al. Rapid discovery of death ligands with one-bead-two-compound combinatorial library methods. ACS Comb Sci 2011;13:259–64.
14. Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H, et al. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis 2014;5:e991.
15. van den Brûle FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 2001;193:80–7.
16. Carlini MJ, Roitman P, Nunez M, Pallotta MG, Boggio G, Smith D, et al. Clinical relevance of galectin-1 expression in non-small cell lung cancer patients. Lung Cancer 2014;84:73–8.
17. Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007;120:2331–8.
18. White NM, Masui O, Newsted D, Scorilas A, Romaschin AD, Bjarnason GA, et al. Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. Br J Cancer 2014;110:1250–9.
19. Martinez-Bosch N, Fernandez-Barrena MG, Moreno M, Ortiz-Zapater E, Munne-Collado J, Iglesias M, et al. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and hedgehog signaling activation. Cancer Res 2014;74:3512–24.
20. Demydenko D, Berest I. Expression of galectin-1 in malignant tumors. Exp Oncol 2009;31:74–9.
21. Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5:29–41.
22. Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001;20:7486–93.
23. Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995;378:736–9.
24. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection. Cancer Cell 2004;5:241–51.
25. Stanley P. Galectin-1 pulls the strings on VEGFR2. Cell 2014;156:625–6.
26. Xiao W, Li T, Bononi FC, Lac D, Kekessie IA, Liu Y, et al. Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of alpha3 integrin-expressing human tumors. EJNMMI Res 2016;6:18.
27. Chou TC, Talalay P. Generalized equations for the analysis of inhibitions of michaelis-menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981;115: 207–16.
28. Hsieh SY, Shih TC, Yeh CY, Lin CJ, Chou YY, Lee YS. Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 2006;6:5322–31.
29. Xiao K, Li Y, Lee JS, Gonik AM, Dong T, Fung G, et al. "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res 2012;72:2100–10.
30. Nicholson DW, Thornberry NA. Caspases: killer proteases. Trends Biochem Sci 1997;22:299–306.
31. Hug H, Los M, Hirt W, Debatin K-M. Rhodamine 110-linked amino acids and peptides as substrates to measure caspase activity upon apoptosis induction in intact cells. Biochemistry 1999;38:13906–11.
32. Julie E, Thuy N, Douglas C, Dafna L, Reuben L. Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype. Int J Oncol 1999;14:217–24.
33. Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008;9:747–58.
34. Jordan MA, Wendell K, Gardiner S, Brent Derry W, Copp H, Wilson L. Mitotic block induced in hela cells by low concentrations of paclitaxel (taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816–25.
35. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699–708.
36. Malingré MM, Terwogt JMM, Beijnen JH, Rosing H, Koopman FJ, Tellingen Ov, et al. Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol 2000;18:2468–75.
37. Kim HJ, Jeon HK, Cho YJ, Park YA, Choi JJ, Do IG, et al. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer 2012;48:1914–21.
38. Szoke T, Kayser K, Baumhakel JD, Trojan I, Furak J, Tiszlavicz L, et al. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 2005;69:167–74.
39. Rotblat B, Niv H, André S, Kaltner H, Gabius HJ, Kloog Y. Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits ras-GTP. Cancer Res 2004;64:3112–8.
40. Tewari AK, Mishra A. Synthesis and antiviral activities of N-substituted-2-substituted-benzimidazole derivatives. Indian J Chem 2006;45B:489–93.
41. Mavrova A, Anichina KK, Vuchev DI, Tsenov JA, Kondeva MS, Micheva MK. Synthesis and antitrichinellosis activity of some 2-substituted-[1,3]thiazolo[3,2-a]benzimidazol-3(2H)-ones. Biorg Med Chem 2005;13:5550–9.
42. Örena İ, Temiza Ö, Yalçna İ, Şenera E, Altanlarb N. Synthesis and antimicrobial activity of some novel 2,5- and/or 6-substituted benzoxazole and benzimidazole derivatives. Eur J Pharm Sci 1998;7:153–60.
43. Valdez J, Cedillo R, Hernández-Campos A, Yépez L, Hernández-Luis F, Navarrete-Vázquez G, et al. Synthesis and antiparasitic activity of 1H-benzimidazole derivatives. Bioorg Med Chem Lett 2002;12:2221–4.
44. Sondhi SM, Rajvanshi S, Johar M, Bharti N, Azam A, Singh AK. Anti-inflammatory, analgesic and antiamoebic activity evaluation of pyrimido[1,6-a]benzimidazole derivatives synthesized by the reaction of ketoisothiocyanates with mono and diamines. Eur J Med Chem 2002;37:835–43.
45. Kumar JR, Jawahar LJ, Pathak DP. Synthesis of benzimidazole derivatives: as anti-hypertensive agents. E J Chem 2006;3:278–85.
46. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.